Cardiol Therapeutics hits 110-patient MAVERIC enrollment target

Cardiol Therapeutics said on September 23, 2026 it hit its 110-patient MAVERIC phase III enrollment target, and the steering committee recommended expanding to 150 patients to strengthen efficacy assessment. Market reaction was pending at publication.

Steering committee expands enrollment

The company said the original 110-patient target was achieved ahead of its end-of-September guidance and that the MAVERIC steering committee recommended increasing enrollment to up to 150 patients to bolster the trial's ability to assess CardiolRx's efficacy. The statement framed the expansion as a step to strengthen the pivotal dataset.

If the recommendation is implemented, the larger sample would raise the trial's statistical power and narrow confidence intervals around efficacy estimates; it could also extend the recruitment timeline and increase trial costs. The company did not disclose an updated completion date or incremental budget in the announcement.

Investors will watch whether the company files any protocol amendment or a formal trial-status update by September 30, 2026, the end-of-month date tied to its prior guidance. Any official revision to enrollment size, timeline or budget could influence expectations for CardiolRx development and the stock's near-term outlook.